WO2009073445A3 - Biocompatible biodegradable fumagillin analog conjugates - Google Patents

Biocompatible biodegradable fumagillin analog conjugates Download PDF

Info

Publication number
WO2009073445A3
WO2009073445A3 PCT/US2008/084539 US2008084539W WO2009073445A3 WO 2009073445 A3 WO2009073445 A3 WO 2009073445A3 US 2008084539 W US2008084539 W US 2008084539W WO 2009073445 A3 WO2009073445 A3 WO 2009073445A3
Authority
WO
WIPO (PCT)
Prior art keywords
fumagillin
fumagillin analog
methods
biocompatible biodegradable
analog
Prior art date
Application number
PCT/US2008/084539
Other languages
French (fr)
Other versions
WO2009073445A2 (en
Inventor
Laura C. Akullian
Russell C. Petter
John J. Kane
Charles E. Hammond
Mao Yin
Aleksandr Yurkovetskiy
Cheri A. Stevenson
Original Assignee
Mersana Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ585547A priority Critical patent/NZ585547A/en
Application filed by Mersana Therapeutics, Inc. filed Critical Mersana Therapeutics, Inc.
Priority to CN2008801221269A priority patent/CN101990441A/en
Priority to MX2010005857A priority patent/MX2010005857A/en
Priority to AU2008331516A priority patent/AU2008331516B2/en
Priority to BRPI0820229A priority patent/BRPI0820229A2/en
Priority to CA2706914A priority patent/CA2706914A1/en
Priority to JP2010536101A priority patent/JP5557746B2/en
Priority to EA201070657A priority patent/EA020251B1/en
Priority to EP08857683A priority patent/EP2217283A2/en
Publication of WO2009073445A2 publication Critical patent/WO2009073445A2/en
Publication of WO2009073445A3 publication Critical patent/WO2009073445A3/en
Priority to ZA2010/03819A priority patent/ZA201003819B/en
Priority to IL206057A priority patent/IL206057A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

Fumagillin analog polymer conjugates, methods of making fumagillin analog polymer conjugates, compositions comprising a polymer conjugate of a fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a polymer conjugate of a fumagillin analog, are described. Also described are novel fumagillin analogs, methods of making fumagillin analogs, compositions comprising at least one fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a fumagillin analog.
PCT/US2008/084539 2007-11-28 2008-11-24 Biocompatible biodegradable fumagillin analog conjugates WO2009073445A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2706914A CA2706914A1 (en) 2007-11-28 2008-11-24 Biocompatible biodegradable fumagillin analog conjugates
CN2008801221269A CN101990441A (en) 2007-11-28 2008-11-24 Biocompatible biodegradable fumagillin analog conjugates
MX2010005857A MX2010005857A (en) 2007-11-28 2008-11-24 Biocompatible biodegradable fumagillin analog conjugates.
AU2008331516A AU2008331516B2 (en) 2007-11-28 2008-11-24 Biocompatible biodegradable fumagillin analog conjugates
BRPI0820229A BRPI0820229A2 (en) 2007-11-28 2008-11-24 biocompatible biodegradable fumagillin analog conjugates
NZ585547A NZ585547A (en) 2007-11-28 2008-11-24 Biocompatible biodegradable fumagillin analog conjugates
JP2010536101A JP5557746B2 (en) 2007-11-28 2008-11-24 Biocompatible biodegradable fumagillin analog complex
EA201070657A EA020251B1 (en) 2007-11-28 2008-11-24 Biocompatible biodegradable fumagillin analog conjugates
EP08857683A EP2217283A2 (en) 2007-11-28 2008-11-24 Biocompatible biodegradable fumagillin analog conjugates
ZA2010/03819A ZA201003819B (en) 2007-11-28 2010-05-27 Biocompatible biodegradable fumagillin analog conjugates
IL206057A IL206057A0 (en) 2007-11-28 2010-05-27 Biocompatible biodegradable fumagillin analog conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US458207P 2007-11-28 2007-11-28
US61/004,582 2007-11-28

Publications (2)

Publication Number Publication Date
WO2009073445A2 WO2009073445A2 (en) 2009-06-11
WO2009073445A3 true WO2009073445A3 (en) 2010-01-28

Family

ID=40600044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/084539 WO2009073445A2 (en) 2007-11-28 2008-11-24 Biocompatible biodegradable fumagillin analog conjugates

Country Status (13)

Country Link
US (2) US8399512B2 (en)
EP (1) EP2217283A2 (en)
JP (1) JP5557746B2 (en)
CN (1) CN101990441A (en)
AU (1) AU2008331516B2 (en)
BR (1) BRPI0820229A2 (en)
CA (1) CA2706914A1 (en)
EA (1) EA020251B1 (en)
IL (1) IL206057A0 (en)
MX (1) MX2010005857A (en)
NZ (2) NZ600039A (en)
WO (1) WO2009073445A2 (en)
ZA (1) ZA201003819B (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE507845T1 (en) * 2003-09-05 2011-05-15 Gen Hospital Corp POLYACETAL DRUG CONJUGATES AS A RELEASE SYSTEM
EA020251B1 (en) 2007-11-28 2014-09-30 Мерсана Терапьютикс, Инк. Biocompatible biodegradable fumagillin analog conjugates
CA2731020A1 (en) 2008-07-18 2010-01-21 Zafgen, Inc. Use of antiangiogenic fumagillins in the treatment of obesity
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
CL2009002167A1 (en) * 2008-12-10 2010-10-15 Mersana Therapeutics Inc Pharmaceutical formulation for intravenous administration comprising a compound derived from biocompatible and biodegradable camptothecin-polymer conjugates, a stabilizing agent, one or more buffers and a surfactant, useful for the treatment of cancer.
JP2012528240A (en) * 2009-05-28 2012-11-12 メルサナ セラピューティックス， インコーポレイテッド Polyal-drug conjugates containing variable rate release linkers
AU2010303270A1 (en) 2009-10-09 2012-05-03 Zafgen Corporation Sulphone compounds for use in the treatment of obesity
CA2786603C (en) 2010-01-08 2018-02-20 James E. Vath Fumagillol type compounds and methods of making and using same
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
EP2553019A1 (en) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
CA2828605C (en) 2010-05-25 2019-01-15 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
BR112013001613A2 (en) 2010-07-22 2016-05-24 Zafgen Inc tricyclic compounds and methods for making and using them.
UA111479C2 (en) 2010-11-09 2016-05-10 Зафджен, Інк. Crystalline solids of a metap-2 inhibitor and methods of making and using same
JP2013543899A (en) 2010-11-29 2013-12-09 ザフゲン，インコーポレイテッド Treatment of obesity with non-daily administration of 6-O- (4-dimethylaminoethoxy) cinnamoyl fumagillol
CA2825408A1 (en) 2011-01-26 2012-08-02 Zafgen, Inc. Tetrazole compounds and methods of making and using same
US9328082B2 (en) 2011-03-08 2016-05-03 Zafgen, Inc. Oxaspiro[2.5]octane derivatives and analogs
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
AU2012253757B2 (en) 2011-05-06 2017-04-13 Zafgen Inc. Partially saturated tricyclic compounds and methods of making and using same
EP2705036B1 (en) 2011-05-06 2015-08-12 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
JP5926374B2 (en) 2011-06-10 2016-05-25 メルサナ セラピューティクス，インコーポレイティド Protein-polymer-drug conjugate
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
WO2013067055A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
TW201332574A (en) * 2011-12-23 2013-08-16 Mersana Therapeutics Inc Pharmaceutical formulations for fumagillin derivative-PHF conjugates
JP6035347B2 (en) 2012-01-18 2016-11-30 ザフゲン，インコーポレイテッド Tricyclic sulfonamide compounds and methods for making and using the same
CA2861381A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US9260419B2 (en) 2012-05-07 2016-02-16 Zafgen, Inc. Polymorphic salt of a metap-2 inhibitor and methods of making and using same
EP2846792B1 (en) 2012-05-08 2018-08-15 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
EP2850079B1 (en) 2012-05-09 2018-05-02 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
US10174009B2 (en) 2012-11-05 2019-01-08 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
KR20150080614A (en) 2012-11-05 2015-07-09 자프겐 인크. Tricyclic compounds for use in the treatment and/or control of obesity
BR112015010196A2 (en) 2012-11-05 2017-07-11 Zafgen Inc methods of treating liver disease
WO2014152861A2 (en) 2013-03-14 2014-09-25 Zafgen, Inc. Methods of treating renal disease and other disorders
CN112494476A (en) 2013-04-10 2021-03-16 新德发制药有限公司 Use of compounds for the treatment of obesity
ES2726850T3 (en) 2013-10-11 2019-10-09 Mersana Therapeutics Inc Protein-polymer-drug conjugates
CN105813655B (en) 2013-10-11 2022-03-15 阿萨纳生物科技有限责任公司 Protein-polymer-drug conjugates
JP6493868B2 (en) * 2014-09-24 2019-04-03 日東電工株式会社 Vinyl monomer having diglycolamide acid type ligand
EP3212668B1 (en) 2014-10-31 2020-10-14 AbbVie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
CA2970155A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
CN107249643A (en) 2014-12-09 2017-10-13 艾伯维公司 The antibody drug conjugate of BCL XL inhibitor with cell permeability
TW201636342A (en) 2014-12-19 2016-10-16 武田藥品工業有限公司 Fumagillol derivatives
AR105671A1 (en) * 2015-08-11 2017-10-25 Zafgen Inc HUMEROCYCLIC COMPOUNDS OF FUMAGILLOL AND ITS METHODS OF ELABORATION AND USE
CN106432255A (en) 2015-08-11 2017-02-22 扎夫根公司 Fumigillol spiro-compound, preparation and use method thereof
JP2019500327A (en) 2015-11-30 2019-01-10 アッヴィ・インコーポレイテッド Anti-huLRRC15 antibody drug conjugate and method of use thereof
EP3383910A1 (en) 2015-11-30 2018-10-10 AbbVie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
EP3386956B1 (en) 2015-12-10 2021-07-14 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
EP3402529A1 (en) 2016-01-11 2018-11-21 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
CN108697799A (en) 2016-03-22 2018-10-23 生态学有限公司 The application of anti-LGR5 monoclonal antibodies
DK3458102T3 (en) 2016-05-17 2020-07-27 Abbvie Biotherapeutics Inc ANTI-CMET ANTIBODY DRUG CONJUGATES AND PROCEDURES FOR USE
CN109641962A (en) 2016-06-08 2019-04-16 艾伯维公司 Anti- B7-H3 antibody and antibody drug conjugates
CR20180614A (en) 2016-06-08 2019-07-29 Abbvie Inc CONJUGATES OF ANTIBODY AND ANTI-EGFR DRUG
WO2017214301A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
JP2019526529A (en) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド Anti-B7-H3 antibody and antibody drug conjugate
CN109600993A (en) 2016-06-08 2019-04-09 艾伯维公司 Anti-egfr antibodies drug conjugates
CN109562169A (en) 2016-06-08 2019-04-02 艾伯维公司 Anti-CD 98 antibody and antibody drug conjugates
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
US20200121803A1 (en) 2016-06-08 2020-04-23 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
PE20190177A1 (en) 2016-06-08 2019-02-01 Abbvie Inc ANTI-B7-H3 ANTIBODIES AND ANTIBODY AND DRUG CONJUGATES
AU2017311597A1 (en) * 2016-08-11 2019-02-28 Zafgen, Inc. Fumagillol compounds and methods of making and using same
KR102617264B1 (en) 2016-10-19 2023-12-29 인벤라 인코포레이티드 antibody structure
EA201991204A1 (en) 2016-12-22 2019-12-30 Университа Дельи Студи Манья Греча Катандзаро MONOCLONAL ANTIBODY AGAINST UNIQUE Sialoglycosylated Tumor-Associated Epitope CD43
CN106831662B (en) * 2016-12-29 2018-12-18 中国农业科学院蜜蜂研究所 A kind of amido polyol is for fumidil and its synthetic method and application
AU2018290330A1 (en) 2017-06-22 2020-01-02 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
WO2019118612A1 (en) * 2017-12-12 2019-06-20 Zafgen, Inc. Targeting compounds
PE20210320A1 (en) 2018-06-01 2021-02-16 Novartis Ag BINDING MOLECULES AGAINST BCMA AND THE USES OF THEM
JP2021527047A (en) 2018-06-05 2021-10-11 キングス・カレッジ・ロンドン BTNL3 / 8 targeting construct for payload delivery to the gastrointestinal system
CA3117666A1 (en) 2018-10-26 2020-04-30 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
US20230071196A1 (en) 2019-05-21 2023-03-09 Novartis Ag Variant cd58 domains and uses thereof
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
JP2022543669A (en) 2019-08-08 2022-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Novel antigen-binding molecule format
TW202134277A (en) 2019-11-05 2021-09-16 美商再生元醫藥公司 N-terminal scfv multispecific binding molecules
AU2021205893A1 (en) 2020-01-08 2022-06-23 Synthis Therapeutics, Inc. ALK5 inhibitor conjugates and uses thereof
CA3174103A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
WO2021195513A1 (en) 2020-03-27 2021-09-30 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
AU2022324456A1 (en) 2021-08-05 2024-02-15 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
AU2022339667A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2023034571A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
WO2023156996A1 (en) * 2022-02-16 2023-08-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Metap2 inhibitors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
WO2003086382A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Tnp-470 polymer conjugates and use thereof
US20040105840A1 (en) * 2002-07-19 2004-06-03 Kinstler Olaf B. Protein conjugates with a water-soluble biocompatible, biodegradable polymer
WO2005023294A2 (en) * 2003-09-05 2005-03-17 The General Hospital Corporation Polyacetal drug conjugates as release system

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2803586A (en) * 1953-06-29 1957-08-20 Abbott Lab ph control in production of fumagillin
US5164410A (en) * 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
US5180738A (en) * 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
JP2858724B2 (en) * 1988-09-01 1999-02-17 武田薬品工業株式会社 Angiogenesis inhibitor
KR0138530B1 (en) * 1988-09-01 1998-05-15 우메모또 요시마사 Fumagillol derivatives
US6017954A (en) * 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
ATE153854T1 (en) * 1992-12-16 1997-06-15 Takeda Chemical Industries Ltd STABLE PHARMACEUTICAL PREPARATION CONTAINING FUMAGILLOL DERIVATIVES
JP3260378B2 (en) * 1995-03-27 2002-02-25 サノフィーサンテラボ Use of fumagillol and its derivatives for the preparation of a drug against intestinal infection
US5811510A (en) * 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
US6207704B1 (en) * 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
WO1999061432A1 (en) 1998-05-12 1999-12-02 Biochem Pharma Inc. Fumagillin analogs and their use as angiogenesis inhibitors
KR100357541B1 (en) * 1998-05-15 2002-10-18 주식회사종근당 5-Demthoxyfumagillol derivatives and processes for preparing the same
KR100357542B1 (en) * 1998-05-15 2002-10-18 주식회사종근당 Fumagillol derivatives and preparation method thereof
US6603812B1 (en) * 1998-08-17 2003-08-05 Linear Technology Corporation Hardware implementation of a decimating finite impulse response filter
AU6409499A (en) * 1998-10-01 2000-04-17 Children's Medical Center Corporation Method of treatment of cardiovascular injuries
ATE361757T1 (en) * 1999-02-26 2007-06-15 Sanofi Aventis STABLE FUMAGILLIN FORMULATION
HUP9901943A2 (en) * 1999-06-11 2001-12-28 Sanofi-Synthelabo New process for producing fumagillin
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6822086B1 (en) * 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
GB0012179D0 (en) * 2000-05-20 2000-07-12 Imp Cancer Res Tech Assays and drug screening systems
EP1330447A2 (en) * 2000-11-01 2003-07-30 Praecis Pharmaceuticals Incorporated Peptides as met-ap2 inhibitors
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7105482B2 (en) * 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
DE60233420D1 (en) * 2001-09-27 2009-10-01 Equispharm Co Ltd Fumagillol derivatives and process for their preparation
US6803382B2 (en) * 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
DE60323936D1 (en) * 2002-01-14 2008-11-20 Gen Hospital Corp BIOABEAABLE POLYCETALES, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE
ATE441706T1 (en) * 2002-02-20 2009-09-15 Gen Hospital Corp BIODEGRADABLE POLYMER CONJUGATES AND USE THEREOF
CA2492803C (en) * 2002-07-19 2013-11-05 The General Hospital Corporation Oxime conjugates and methods for their formation and use
FR2872511B1 (en) * 2004-06-30 2006-08-11 Galderma Res & Dev NOVEL INHIBITORS OF ANGIOGENESIS AND THEIR PHARMACEUTICAL AND COSMETIC USE
AU2006247471A1 (en) * 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
JP5364875B2 (en) * 2007-07-16 2013-12-11 アッヴィ・インコーポレイテッド Indazoles, benzisoxazoles and benzisothiazoles as protein kinase inhibitors
EA020251B1 (en) 2007-11-28 2014-09-30 Мерсана Терапьютикс, Инк. Biocompatible biodegradable fumagillin analog conjugates
JP2012528240A (en) * 2009-05-28 2012-11-12 メルサナ セラピューティックス， インコーポレイテッド Polyal-drug conjugates containing variable rate release linkers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
WO2003086382A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Tnp-470 polymer conjugates and use thereof
US20040105840A1 (en) * 2002-07-19 2004-06-03 Kinstler Olaf B. Protein conjugates with a water-soluble biocompatible, biodegradable polymer
WO2005023294A2 (en) * 2003-09-05 2005-03-17 The General Hospital Corporation Polyacetal drug conjugates as release system
US20070190018A1 (en) * 2003-09-05 2007-08-16 Papisov Mikhail I Dual phase drug release system

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKULLIAN LC ET AL.: "Abstract 2327: Fumagillin-derived polymeric pro-drugs exhibit anti-tumor activity in B16 murine melanoma and in A2058 and PC3 human tumor xenograft models", 99TH AACR ANNUAL MEETING, 12 April 2008 (2008-04-12) - 16 April 2008 (2008-04-16), San Diego, CA US, XP002543987, Retrieved from the Internet <URL:http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/2327?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&andorexacttitle=and&andorexacttitleabs=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&fdate=1/1/2004&tdate=12/31/2008&resourcetype=HWCIT> [retrieved on 20090901] *
BERNIER S G ET AL: "Fumagillin class inhibitors of methionine aminopeptidase-2", DRUGS OF THE FUTURE, vol. 30, no. 5, May 2005 (2005-05-01), pages 497 - 508, XP008097519, ISSN: 0377-8282 *
PYUN H -J ET AL: "Investigation of novel fumagillin analogues as angiogenesis inhibitors", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 1, 5 January 2004 (2004-01-05), GB, pages 91 - 94, XP002543988, ISSN: 0960-894X *
YASUKAWA T ET AL: "Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, vol. 40, no. 11, 1 October 1999 (1999-10-01), US, pages 2690 - 2696, XP002382876, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
IL206057A0 (en) 2010-11-30
WO2009073445A2 (en) 2009-06-11
US20130158046A1 (en) 2013-06-20
AU2008331516A1 (en) 2009-06-11
EA020251B1 (en) 2014-09-30
JP2011504964A (en) 2011-02-17
EA201070657A1 (en) 2010-12-30
NZ585547A (en) 2012-12-21
US8399512B2 (en) 2013-03-19
BRPI0820229A2 (en) 2017-05-09
AU2008331516B2 (en) 2014-01-09
CA2706914A1 (en) 2009-06-11
JP5557746B2 (en) 2014-07-23
EP2217283A2 (en) 2010-08-18
US20090148396A1 (en) 2009-06-11
MX2010005857A (en) 2010-11-22
CN101990441A (en) 2011-03-23
NZ600039A (en) 2013-11-29
ZA201003819B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
WO2009073445A3 (en) Biocompatible biodegradable fumagillin analog conjugates
WO2011015634A3 (en) Controlled release formulations of lipocalin muteins
WO2006014673A3 (en) Insulin-oligomer conjugates, formulations and uses thereof
EP2963031A3 (en) Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
MX2008001706A (en) Conjugates of a g-csf moiety and a polymer.
WO2007035612A3 (en) Polyphenol conjugates as rgd-binding compounds and methods of use
WO2006005058A3 (en) Polymer-factor ix moiety conjugates
WO2007100905A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
EP2422819A3 (en) Compositions and their uses directed to Huntingtin
UA91575C2 (en) Four branched dendrimer-peg for conjugation to proteins and peptides
WO2009081169A8 (en) Biodegradable contrast agents
NZ590569A (en) Factor viii polymer conjugates
MY158504A (en) Fatty acid niacin conjugates and their uses
WO2010009111A3 (en) A drug depot implantable within a synovial joint
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
WO2009123934A3 (en) Branched multifunctional nanoparticle conjugates and their use
DE602005025355D1 (en) CONJUGATE CONTAINS GM-CSF AND A POLYMER
MX2012010448A (en) Carbohydrate-polyamino acid-drug conjugates.
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2007117605A3 (en) Novel spill-resistant formulations comprising hydrocolloidal polymers
WO2009001209A8 (en) Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases
WO2010080720A3 (en) Conjugates of a lysosomal enzyme moiety and a water soluble polymer
WO2009139905A3 (en) Conjugates of a cholinesterase moiety and a polymer
WO2009132234A3 (en) Medical devices, polymers, compositions, and methods for delivering a haloacetate
WO2005041881A8 (en) Taxoid-fatty acid conjugates and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880122126.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08857683

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2008857683

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008331516

Country of ref document: AU

Ref document number: 2008857683

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 585547

Country of ref document: NZ

Ref document number: 2010536101

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2706914

Country of ref document: CA

Ref document number: 1916/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 206057

Country of ref document: IL

Ref document number: MX/A/2010/005857

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008331516

Country of ref document: AU

Date of ref document: 20081124

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201070657

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0820229

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100528